Robert Dickey IV
AIM ImmunoTechAbout Robert Dickey IV
Robert Dickey IV, age 70, has served as Chief Financial Officer of AIM ImmunoTech since April 4, 2022; he previously served as a senior vice president of the Company from 2008 to 2013 and currently leads disclosure processes as Chair and Investor Relations Coordinator of AIM’s Disclosure Controls Committee . He was engaged via a consulting agreement with his firm, Foresite Advisors, at $375 per hour beginning March 1, 2022, under which he serves as CFO . Company performance context during his tenure includes a decline in total shareholder return (TSR) from $47.83 (value of $100 investment) in 2023 to $21.52 in 2024, alongside net losses of ~$28.96M (2023) improving to ~$17.32M (2024) .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| AIM ImmunoTech Inc. | Chief Financial Officer | Apr 4, 2022–present | Executive finance leadership; chairs Disclosure Controls Committee (IR Coordinator) overseeing public disclosures |
| AIM ImmunoTech Inc. | Senior Vice President | 2008–2013 | Senior financial leadership at AIM in earlier tenure |
| Foresite Advisors, LLC | Managing Director | Mar 2020–present | CFO advisory, capital raising, and transaction execution for life science companies |
| Lehman Brothers (Investment Banking) | M&A and Capital Markets roles | 18 years (earlier career) | Extensive M&A/capital markets execution experience; C‑suite roles across life sciences thereafter |
External Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| AngioGenex | Director | Current | Board oversight in life sciences; industry network leverage |
| SFA Therapeutics | Director | Current | Board oversight; governance and financing perspective |
| GSNO Therapeutics | Director | Current | Board oversight; finance/transaction expertise |
Fixed Compensation
| Metric ($) | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|
| Base salary/fees | 37,815 | 54,484 | 49,549 |
| Target bonus % | Not disclosed | Not disclosed | Not disclosed |
| Actual bonus paid | 10,000 | 10,000 | — (waived) |
| Stock awards (fair value) | — | — | — (executives waived 2024 option awards) |
| Option awards (fair value) | — | — | — (options for 2024 were waived) |
| All other compensation | — | — | — |
| Total compensation | 47,815 | 64,484 | 49,549 |
Notes:
- AIM disclosed issuing common stock in lieu of cash salaries to “certain NEOs” in 2024 totaling $250,000 (aggregate), as part of cash conservation; individual allocations were not broken out .
- Executives voluntarily waived all 2024 bonus compensation and 2024 option awards to conserve cash .
Performance Compensation
Incentive design and performance metrics
- The Compensation Committee states it ties a substantial portion of executive compensation to “key strategic financial and operational goals” (e.g., strategic relationships, product development/advancement, additional products) and Company stock price performance; specific metric weightings/targets for the CFO were not disclosed due to smaller reporting company scaled disclosures .
- At the 2024 Annual Meeting, stockholders did not approve the advisory vote on executive compensation (failed say‑on‑pay), which the Committee states it is factoring into plan design going forward .
Given the absence of detailed metric tables for the CFO, no per‑metric weighting/target/actual/payout schedule is disclosed for 2022–2024 .
Equity awards and vesting/pressure
| Instrument | Grant/Identifier | Quantity | Exercise/Strike | Vesting status | Expiration |
|---|---|---|---|---|---|
| Non‑qualified stock options | Outstanding at FY‑end | 500 (exercisable) | $70.00 | Fully exercisable; no unexercisable options listed | 03/03/2032 |
Notes:
- Executives waived 2024 option awards in support of cash conservation .
- Proxy states the company does not prohibit employees or directors from engaging in hedging transactions (e.g., collars, swaps), a governance red flag for alignment; no specific pledging disclosures for Mr. Dickey were found .
Equity Ownership & Alignment
Beneficial ownership snapshots (note the share count base changed materially between dates):
- As of March 24, 2025 (10‑K FY 2024): Robert Dickey IV beneficially owned 50,000 shares (all via options), less than 1% of outstanding shares (72,290,030 total shares) .
- As of October 24, 2025 (DEF 14A): Robert Dickey IV beneficially owned 500 shares (via exercisable options), less than 1% of outstanding shares (2,764,188 total shares) .
Ownership breakdown and guidelines:
- Vested vs. unvested: 500 options listed as exercisable; no unexercisable options reported for Mr. Dickey at FY‑end .
- Shares pledged as collateral: No pledging disclosure found for Mr. Dickey; Company discloses no prohibition on hedging transactions for insiders .
- Stock ownership guidelines: Not disclosed in the proxy under scaled SRC disclosures .
Employment Terms
| Term | Detail |
|---|---|
| Engagement | Consulting agreement with Foresite Advisors, LLC (wholly owned by Mr. Dickey) at $375/hour beginning March 1, 2022; serves as CFO effective April 4, 2022 |
| Start date in role | April 4, 2022 (CFO) |
| Severance | Mr. Dickey is not covered by an employment severance agreement; any severance would be at Compensation Committee discretion |
| Change‑in‑control | The proxy describes CIC extensions/benefits for CEO/COO; it also states “any purchase rights represented by an Option not then vested shall, upon a change in control, become vested” (general option treatment). No specific CIC cash multiple disclosed for the CFO |
| Non‑compete / non‑solicit | Not disclosed for CFO under SRC scaled disclosures |
| Clawbacks / gross‑ups | Not specifically disclosed for CFO; no anti‑hedging prohibition for employees/directors is disclosed |
Investment Implications
- Alignment and selling pressure: Mr. Dickey’s disclosed equity exposure is minimal (500 exercisable options as of the October 24, 2025 record date), implying limited immediate insider selling pressure from vesting schedules; lack of meaningful ownership reduces direct pay‑for‑performance alignment versus larger equity‑based CFO packages common in biotech .
- Retention and transition risk: His CFO role is delivered through a consulting arrangement with no fixed severance protection; while flexible for cash conservation, this structure can elevate retention risk in adverse scenarios relative to standard employment contracts with CIC/severance terms .
- Governance red flags: Shareholders failed say‑on‑pay in 2024, and the Company has no prohibition on hedging by insiders—both signaling potential misalignment and elevating governance risk premia in valuation .
- Pay conservatism and cash preservation: Executives waived 2024 bonuses and option grants; the Company also used stock in lieu of cash salary for certain NEOs in 2024, consistent with liquidity preservation. This reduces cash burn but leaves less equity‑based retention for the CFO, potentially necessitating future re‑equitization if performance improves .
- Performance backdrop: TSR fell from $47.83 to $21.52 (value of $100 investment) from 2023 to 2024 while net losses narrowed from ~$28.96M to ~$17.32M, indicating financial improvements but continued value pressure; incentive metrics are framed broadly (strategic/stock price) without disclosed targets/weights, limiting external assessment of pay‑for‑performance rigor for the CFO .
Citations
- Executive role, age, and background:
- Consulting agreement, hourly rate, CFO effective date:
- Compensation tables, waivers, and stock‑in‑lieu notes:
- Outstanding equity awards (options detail):
- Beneficial ownership snapshots and share counts:
- Severance/CIC terms (scope and option acceleration):
- Anti‑hedging disclosure:
- Say‑on‑pay outcome (failed 2024):
- Pay‑versus‑performance (TSR and net losses):